SEC Form 4 · accession 0001192482-15-000369
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Rapp
10% Owner
Period of report
Aug 10, 2015
Accepted (ET)
Aug 10, 2015 · 3:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 10, 2015 | C | 567,505 | — | A | 1,263,648 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series 1 Convertible Preferred StockF1,F2 | — | Aug 10, 2015 | C | 1,066,911 | D | — | — | Common Stock | 567,505 | 0 | D |
Explanation of responses
- F1The Series 1 Convertible Preferred Stock converted into Zynerba Pharmaceuticals, Inc. common stock on a 1.88-for-1 basis.
- F2The Series 1 Convertible Preferred Stock had no expiration date.